- Home
- YHC vs BCLI Comparison
YHC vs BCLI Comparison
Compare YHC & BCLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHC
- BCLI
- Stock Information
- Founded
- YHC 2021
- BCLI 2000
- Country
- YHC United States
- BCLI United States
- Employees
- YHC N/A
- BCLI N/A
- Industry
- YHC Beverages (Production/Distribution)
- BCLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YHC Consumer Staples
- BCLI Health Care
- Exchange
- YHC Nasdaq
- BCLI Nasdaq
- Market Cap
- YHC 12.3M
- BCLI 13.5M
- IPO Year
- YHC N/A
- BCLI N/A
- Fundamental
- Price
- YHC $0.83
- BCLI $1.74
- Analyst Decision
- YHC
- BCLI Strong Buy
- Analyst Count
- YHC 0
- BCLI 1
- Target Price
- YHC N/A
- BCLI $30.00
- AVG Volume (30 Days)
- YHC 54.0K
- BCLI 52.8K
- Earning Date
- YHC 03-31-2025
- BCLI 03-31-2025
- Dividend Yield
- YHC N/A
- BCLI N/A
- EPS Growth
- YHC N/A
- BCLI N/A
- EPS
- YHC N/A
- BCLI N/A
- Revenue
- YHC $2,272,001.00
- BCLI N/A
- Revenue This Year
- YHC $120.06
- BCLI N/A
- Revenue Next Year
- YHC $72.42
- BCLI N/A
- P/E Ratio
- YHC N/A
- BCLI N/A
- Revenue Growth
- YHC 158.05
- BCLI N/A
- 52 Week Low
- YHC $0.40
- BCLI $1.05
- 52 Week High
- YHC $2.45
- BCLI $11.85
- Technical
- Relative Strength Index (RSI)
- YHC N/A
- BCLI 42.17
- Support Level
- YHC N/A
- BCLI $1.69
- Resistance Level
- YHC N/A
- BCLI $1.93
- Average True Range (ATR)
- YHC 0.00
- BCLI 0.16
- MACD
- YHC 0.00
- BCLI -0.04
- Stochastic Oscillator
- YHC 0.00
- BCLI 13.93
About BCLI Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.